Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of doraglutide to medicine for treating and preventing intrauterine adhesion

A technology of dulaglutide and intrauterine adhesions, applied in the field of reproductive endocrine, can solve the problems of endometrium loss of regenerative ability, achieve the effect of increasing the thickness and number of glands, reducing the degree of fibrosis, and reducing ECM deposition

Pending Publication Date: 2021-08-31
THE FIRST HOSPITAL OF LANZHOU UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Injured endometrial stromal cells produce a large amount of ECM and induce an inflammatory response, resulting in the loss of endometrial regeneration ability
However, there are no studies on dulaglutide in the treatment of endometrial fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of doraglutide to medicine for treating and preventing intrauterine adhesion
  • Application of doraglutide to medicine for treating and preventing intrauterine adhesion
  • Application of doraglutide to medicine for treating and preventing intrauterine adhesion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] Application of dulaglutide in the treatment and prevention of intrauterine adhesions.

[0025] The dulaglutide is prepared into 12-15ml of dulaglutide liquid medicine. The administration cycle of dulaglutide liquid medicine is 1 time / week for 14 consecutive days.

[0026] Wherein: the preparation of the dulaglutide medicinal solution refers to the preparation by dissolving the dulaglutide in a sterile 1x PBS solution according to the corresponding concentration.

[0027] The dosage of dulaglutide is 150μg / Kg~600μg / Kg.

[0028] 【Effect of Dulaglutide on Histomorphology of IUA in Mice】

[0029] The IUA mouse model was established by the method of "mechanical injury + infection" combined modeling, and the effect of dulaglutide on the histomorphology of mouse IUA was determined by observing the general shape of the uterus and the results of histopathological staining.

[0030]⑴Experimental animal model:

[0031] C57BL / 6J mice, 8 weeks old, 16g to 18g, 36 in total. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of doraglutide to a medicine for treating and preventing intrauterine adhesion. The doraglutide is made into 12-15 milliliters of doraglutide liquid medicines. An IUA mouse model is established by adopting a mechanical injury and infection combined modeling method, and after the IUA model is subjected to uterine curettage and LPS dual induction, the gland number of endometrium is reduced, the fibrosis degree is increased, and ECM and EMT accumulation is increased, so that inflammation-mediated endometrial injury plays an important role in activating IUA.

Description

technical field [0001] The invention relates to the technical field of reproductive endocrinology, in particular to the application of dulaglutide in the treatment and prevention of intrauterine adhesions. Background technique [0002] Endometrial fibrosis, also known as intrauterine adhesion (IUA), is the result of endometrial injury. In 1894, Heinrich Fritsch reported the first IUA case. In 1948, Joseph Asherman made a comprehensive description of the IUA case. He first described the complete or partial occlusion of the uterine cavity and (or) cervical canal, and believed that IUA was the result of endometrial trauma. The main pathological changes of IUA are inflammation and accumulation of fibrinogen in the extracellular matrix (ECM), leading to endometrial fibrosis, and ultimately lead to oligomenorrhea, amenorrhea, subfertility, and infertility. IUA is usually caused by trauma, infection, congenital uterine malformation and genetic susceptibility, etc., resulting in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/26A61P41/00A61P15/00
CPCA61K38/26A61P41/00A61P15/00
Inventor 王一青王奕翔武露明
Owner THE FIRST HOSPITAL OF LANZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com